Effectiveness of treat-to-target cholesterol-lowering interventions on cardiovascular disease and all-cause mortality risk in the community-dwelling population: a target trial emulation

Nat Commun. 2024 Nov 15;15(1):9922. doi: 10.1038/s41467-024-54078-4.

Abstract

Little is known about the long-term effectiveness of risk-based treat-to-target cholesterol-lowering interventions on cardiovascular risk. Here, we show the emulated effectiveness of guideline-recommended low-density and non-high-density lipoprotein cholesterol-lowering interventions using the absolute risk reduction (ARR) and the restricted mean event-free time-based number needed to treat (NNT). With 5,375 participants, the 29-year risks for cardiovascular disease (CVD), all-cause mortality, and atherosclerotic CVD were 18.6%, 25.6%, and 17.7%, respectively. Long-term treat-to-target interventions showed significant reductions in CVD (ARR -2.3%, 95%CI -3.4% to -0.8%; NNT 115), all-cause mortality (-3.0%, -4.3% to -1.8%; 95), and atherosclerotic CVD (-2.6%, -3.5% to -1.2%; 104). Such effects appear more pronounced in women, smokers, and those with body mass index < 24 kg/m² or higher adherence rates.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Anticholesteremic Agents / therapeutic use
  • Cardiovascular Diseases* / drug therapy
  • Cardiovascular Diseases* / mortality
  • Cardiovascular Diseases* / prevention & control
  • Cholesterol / blood
  • Cholesterol, LDL / blood
  • Female
  • Humans
  • Independent Living
  • Male
  • Middle Aged
  • Risk Factors

Substances

  • Cholesterol, LDL
  • Anticholesteremic Agents
  • Cholesterol